Get the Stockscreener App
0.0667
80.94%
-0.2833
Orgenesis Inc stock is traded at $0.0667, with a volume of 302.
It is down -80.94% in the last 24 hours and down -94.39% over the past month.
See More
Previous Close:
$0.35
Open:
$0.59
24h Volume:
302
Relative Volume:
1.44
Market Cap:
$N/A
Revenue:
$1.04M
Net Income/Loss:
$-49.01M
P/E Ratio:
-0.006
EPS:
-11.109
Net Cash Flow:
$-17.34M
1W Performance:
-80.94%
1M Performance:
-94.39%
6M Performance:
-94.39%
1Y Performance:
-94.39%
1-Day Range:
$0.0667
$0.59
1-Week Range:
$0.0667
$0.59
52-Week Range:
$0.0327
$0.59
Orgenesis Inc Stock (ORGS) Company Profile
Compare ORGS vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGS
Orgenesis Inc
|
0.0667 | 0 | 1.04M | -49.01M | -17.34M | -11.11 |
VRTX
Vertex Pharmaceuticals Inc
|
522.53 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
811.00 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
183.91 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
970.54 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
367.46 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Orgenesis Inc Stock (ORGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-18 | Initiated | Dawson James | Buy |
Orgenesis Inc Stock (ORGS) Latest News
Alliance Entertainment Adjusted EPS Rises 24% Despite GAAP Profit Decline - minichart.com.sg
Orgenesis Stock Price Forecast. Should You Buy ORGS? - StockInvest.us
Orgenesis Inc (NASDAQ: ORGS) Share Price, ORGS Stock News, ORGS Share Price & Updates - Kalkine
Orgenesis Inc. (ORGS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Orgenesis Inc. (ORGS) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Enterprise value to revenue forward of Orgenesis, Inc. – OTC:ORGS - TradingView
Orgenesis, Inc. Revenue Breakdown – OTC:ORGS - TradingView
Price to earnings forward of Orgenesis, Inc. – OTC:ORGS - TradingView
Future Perspectives: Key Trends Shaping the Cell Therapy Human Raw Materials Market Until 2029 - openpr.com
Top Companies Developing Cell Therapy Treatments For Diabetes in 2026 - BioInformant
Zeo ScientifiX, Inc. (ZEOX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Orgenesis stock reflects restructuring as revenue pivots toward POCare platform - Ad-hoc-news.de
If You Invested $1,000 in Vaxxinity, Inc. (VAXX) - Stock Titan
Orgenesis focuses on cell therapy manufacturing as investors weigh long-term growth prospects - Ad-hoc-news.de
Impact of buying a Hyundai or Genesis - WKRG
Orgenesis adjusts its cell-therapy focus, shares trade quietly on Nasdaq - AD HOC NEWS
Orgenesis Shareholders Approve Major Charter and Stock Increase - TipRanks
SOPAQ Stock Price and Chart — OTC:SOPAQ - TradingView
Orgenesis Inc stock (US68621F1021): delisting to OTC puts spotlight on business model and risks - AD HOC NEWS
UZX Stock Price and Chart — NASDAQ:UZX - TradingView
Orgenesis stock (US68621F1021): cell and gene therapy specialist updates investors amid ongoing rest - AD HOC NEWS
Orgenesis Inc. (ORGS) Surges 79,400% on Penny Stock Rebound - Meyka
Corvus Pharmaceuticals Reports Positive Final Phase 1 Results for Soquelitinib in Atopic Dermatitis at SID 2026 Annual Meeting 16 - Minichart
Orgenesis stock (US68621F1021): Recent clinical trial progress draws investor attention - AD HOC NEWS
MSN Money - MSN
Orgenesis | DEF 14A: Definitive information statements - Moomoo
Competitive Analysis: Key Market Leaders and Emerging - openPR.com
ACNB Corporation Files Q1 2026 Results and Press Release with SEC – Financial Statements and Key Disclosures - Minichart
ALP Stock Price and Chart — NASDAQ:ALP - TradingView
ORGS | ORGENESIS INC Insider Trading - Quiver Quantitative
Viral Vector Production (Research-use) Market Size to Surpass USD 8.51 Billion by 2035 - BioSpace
Gold, Silver Futures Rise Pre-Bell as Sliding Crude Oil Futures Help Limit Inflation Concerns - marketscreener.com
Orgenesis Inc stock (US68621F1021): Is its cell therapy pivot strong enough to unlock biotech upside - AD HOC NEWS
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
ORGS (Orgenesis) PB Ratio : (As of Mar. 31, 2026) - gurufocus.com
Stock List: Research Stocks from Around the World - GuruFocus
Europe Stocks: Research Stocks from Europe Stock Market - GuruFocus
CYAB Stock Price and Chart — NASDAQ:CYAB - TradingView
Orgenesis Inc. 2024 Annual 10-K Report: Financials, Equity, and Major Agreements Overview - Minichart
ORGS: Severe liquidity issues and a $49M net loss raise substantial doubt about ongoing operations - TradingView
Orgen 2023 Form 10-K: $1.035M Revenue, $(49.01)M Net Loss - TradingView
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio - StreetInsider
Okogen Expands Antiviral Pipeline with Ranpirnase Acquisition, Targeting Multiple Therapeutic Areas - citybuzz.co
Okogen, Inc. acquired Global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc.. - marketscreener.com
Orgenesis Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Orgenesis Inc stock advances on cellular therapy breakthroughs amid biotech funding surge - ad-hoc-news.de
Orgenesis Inc stock advances on new cell therapy partnership amid biotech rally - AD HOC NEWS
Orgenesis Expands Board and Appoints New Chief Financial Officer - The Globe and Mail
Orgenesis appoints new directors and chief financial officer By Investing.com - Investing.com Australia
Orgenesis appoints new directors and chief financial officer - Investing.com
Orgenesis Inc Stock (ORGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.21%
Cap:
|
Volume (24h):